- Germline findings in patients with advanced malignancies screened with paired blood–tumour testing for personalised treatment approaches.
- Roggia C, Armeanu-Ebinger S, Gschwind A, Seibel-Kelemen O, Hertler S, Faust U, Liebmann A, Haack TB, Neumann M, Bonzheim I, Forschner A, Kopp HG, Herster F, Hartkopf A, Bitzer M, Malek NP, Brecht IB, Ruhm K, Möller Y, Löwenheim H, Ossowski S, Rieß OH, Schroeder C.
- Eur J Cancer. 2023 Jan 1;179:48-55. doi: 10.1016/j.ejca.2022.11.003. Epub ahead of print.
- Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
- Jiao Y, Truong T, Eon-Marchais S, Mebirouk N, Caputo S, Dondon MG, Karimi M, Le Gal D, Beauvallet J, Le Floch É, Dandine-Roulland C, Bacq-Daian D, Olaso R, Albuisson J, Audebert-Bellanger S, Berthet P, Bonadona V, Buecher B, Caron O, Cavaillé M, Chiesa J, Colas C, Collonge-Rame MA, Coupier I, Delnatte C, De Pauw A,Dreyfus H,Fert-Ferrer S, Gauthier-Villars M, Gesta P, Giraud S, Gladieff L, Golmard L, Lasset C, Lejeune-Dumoulin S, Léoné M, Limacher JM, Lortholary A, Luporsi É, Mari V, Maugard CE, Mortemousque I, Mouret-Fourme E, Nambot S, Noguès C, Popovici C, Prieur F, Pujol P, Sevenet N, Sobol H, Toulas C, Uhrhammer N, Vaur D, Venat L, Boland-Augé A, Guénel P, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F.
- Eur J Cancer. 2023 Jan 1;179:76-86. doi: 10.1016/j.ejca.2022.11.007. Epub ahead of print.
- Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.
- Nourieh M, Vibert R, Saint-Ghislain M, Cyrta J, Vincent-Salomon A.
- Histopathology. 2023 Jan;82(1):162-169. doi: 10.1111/his.14794.
- PMID: 36482269
- PubMed abstract
- Source abstract
- Review
- Free Full Text
- Lessons learned with a longer follow-up from SOLO 1.
- Paulino E.
- J Gynecol Oncol. 2023 Jan;34:e29. doi: 10.3802/jgo.2023.34.e29. Epub 2022 Dec 7.
- Letter
- Free Full Text
- Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report.
- Bian Y, Guan P, Li D, Tan L, Pang H, Wen Q, Chen P, Zhang Z.
- Front Oncol. 2022 Dec 15;12:1071383. doi: 10.3389/fonc.2022.1071383.
- Case report
- Free Full Text
- FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC.
- Harris J.
- OncLive. 2022 Dec 15.
- News
- Free Full Text
•• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Dec 15.)
- Evaluation of out-of-pocket pay genetic testing in a publicly funded healthcare system.
- Grant P, Cook CB, Langlois S, Nuk J, Mung S, Zhang Q; GenCOUNSEL Study, Lynd LD, Austin J, Elliott AM.
- Clin Genet. 2022 Dec 11. doi: 10.1111/cge.14276. Epub ahead of print.
- PMID: 36504324
- PubMed abstract
- Source abstract